問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

Division of Radiation Therapy

更新時間：2023-09-19

廖繼鼎Liau, Chi-Ting
  • Principal Investigator
  • Clinical Trial Experience (year) 24 years

Recruiting Trial

33Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

廖繼鼎

List

81Cases

2016-01-06 - 2024-01-24

Phase III

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians' Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

  • Condition/Disease

    Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus

  • Test Drug

    KEYTRUDA

Participate Sites
3Sites

Terminated3Sites

2015-04-01 - 2023-12-31

Phase III

A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

  • Condition/Disease

    Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

  • Test Drug

    Pembrolizumab (MK-3475)

Participate Sites
6Sites

Terminated5Sites

楊慕華
Taipei Veterans General Hospital

Division of Hematology & Oncology

王宏銘
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2019-05-01 - 2023-05-02

Phase II

A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) With HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN)

  • Condition/Disease

    Head and Neck Squamous Cell Carcinoma (HNSCC)

  • Test Drug

    Tipifarnib

Participate Sites
8Sites

Recruiting6Sites

Terminated2Sites

2010-07-01 - 2011-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2007-09-01 - 2009-09-15

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2016-01-01 - 2017-06-30

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Study ended1Sites

2016-07-01 - 2019-12-31

Phase I/II

A Phase I/ II Study of CAN008 Plus Concomitant Temozolomide During and After Radiation Therapy in Patients with Newly Diagnosed Glioblastoma Multiforme

  • Condition/Disease

    Glioblastoma Multiforme (GBM)

  • Test Drug

    CAN008(APG101)

Participate Sites
3Sites

Terminated3Sites

魏國珍
Linkou Chang Gung Medical Foundation

Division of General Surgery

2018-07-01 - 2021-12-31

Phase III

A Phase III, Randomized, Placebo Controlled, Multicenter, Double-Blind Study Comparing Toripalimab Injection (JS001) Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Recurrent or Metastatic Nasopharyngeal Cancer

  • Condition/Disease

    Nasopharyngeal Cancer

  • Test Drug

    JS001

Participate Sites
8Sites

Terminated7Sites

王宏銘
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

楊慕華
Taipei Veterans General Hospital

Division of Hematology & Oncology

2022-04-15 - 2023-10-11

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2015-09-07 - 2020-06-30

Phase III

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin Plus Olaratumab Versus Doxorubicin Plus Placebo in Patients With Advanced or Metastatic Soft Tissue Sarcoma

  • Condition/Disease

    Advanced or Metastatic Soft Tissue Sarcoma

  • Test Drug

    Olaratumab (LY3012207)

Participate Sites
3Sites

Terminated3Sites

顏厥全
Taipei Veterans General Hospital

Division of General Internal Medicine

1 5 6 7 8 9
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB